跳轉至內容
Merck
全部照片(1)

Key Documents

C2510000

Codergocrine mesilate

European Pharmacopoeia (EP) Reference Standard

同義詞:

Ergoloid mesylate salt, Dihydroergotoxin mesylate salt

登入查看組織和合約定價


About This Item

CAS號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

codergocrine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

CS(O)(=O)=O.CC(CO)NC(=O)C1CC2C(Cc3c[nH]c4cccc2c34)N(C)C1

InChI

1S/C19H25N3O2.CH4O3S/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13;1-5(2,3)4/h3-5,8,11,13,15,17,20,23H,6-7,9-10H2,1-2H3,(H,21,24);1H3,(H,2,3,4)

InChI 密鑰

ONYMVHQTXOEAOV-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Codergocrine mesilate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Chaoqun Yu et al.
International journal of pharmaceutics, 375(1-2), 16-21 (2009-06-09)
The aim of this investigation was to prepare ergoloid mesylate submicron emulsions (EMSEs) for enhancing nasal absorption of drug and reducing nasal ciliotoxicity. Following intranasal administrations of EMSE and ergoloid mesylate solution (EMS) and intravenous administration of EMS to rats
Drugs to treat Alzheimer's disease.
Journal of psychosocial nursing and mental health services, 47(4), 13-14 (2009-05-15)
E V Iarnykh et al.
Terapevticheskii arkhiv, 72(11), 47-50 (2001-03-29)
To assess a hypotensive effect of redergin (dihydroergotoxin)--agonist of dopaminergic receptors--in monotherapy (4.5-6 mg/day) and in combination with enalapril and amlodipin (10 mg/day). Redergin in monotherapy or combined therapy was given to 106 hypertensive women in pre- or postmenopause and
J Olin et al.
The Cochrane database of systematic reviews, (2)(2), CD000359-CD000359 (2000-05-05)
Currently hydergine is used almost exclusively for treating patients with either dementia, or 'age-related' cognitive symptoms. Since the early eighties there have been over a dozen more clinical trials, yet hydergine's efficacy remains uncertain. Although previous reviews offer generally favorable
[Can a hydergine therapy lead to damage of the coronary vessels?].
Frank Ulrich Müller
Deutsche medizinische Wochenschrift (1946), 127(25-26), 1401-1401 (2002-07-24)

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務